Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials near Detroit, MI

77 studies for Breast Cancer are recruiting at 415 sites within 50 miles of Detroit, Michigan, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near Detroit.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Breast Cancer studies enrolling near Detroit

Showing the 50 nearest of 77 studies.
  1. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Henry Ford Health Saint John Hospital (Detroit, MI); Henry Ford Hospital (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    47 sites within 50 mi
  2. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    NCT05334069

    • Observational
    • Ages 40 to 75 years
    • Sex: All
    • Accepts healthy volunteers

    Nearest sites: Henry Ford Health Saint John Hospital (Detroit, MI); Henry Ford Hospital (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    45 sites within 50 mi
  3. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female

    Nearest sites: Henry Ford Health Saint John Hospital (Detroit, MI); Henry Ford Hospital (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    37 sites within 50 mi
  4. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All

    Nearest sites: Henry Ford Health Saint John Hospital (Detroit, MI); Henry Ford Hospital (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    33 sites within 50 mi
  5. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    NCT06058377

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Henry Ford Health Saint John Hospital (Detroit, MI); Henry Ford Hospital (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    32 sites within 50 mi
  6. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Henry Ford Health Saint John Hospital (Detroit, MI); Henry Ford Hospital (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    29 sites within 50 mi
  7. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    NCT03723928

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Ascension Saint John Hospital (Detroit, MI); Academic Hematology Oncology Specialists (Grosse Pointe Woods, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    27 sites within 50 mi
  8. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Henry Ford Hospital (Detroit, MI); Henry Ford Medical Center-Fairlane (Dearborn, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    19 sites within 50 mi
  9. The Vanguard Study: Testing a New Way to Screen for Cancer

    NCT06995898

    • Interventional
    • Ages 45 to 75 years
    • Sex: All
    • Accepts healthy volunteers

    Nearest sites: Henry Ford Hospital (Detroit, MI); Henry Ford Medical Center - Detroit Northwest (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    14 sites within 50 mi
  10. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    NCT03418961

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Henry Ford Hospital (Detroit, MI); Wayne State University/Karmanos Cancer Institute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    12 sites within 50 mi
  11. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    NCT07391774

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Henry Ford Hospital (Detroit, MI); Henry Ford Medical Center-Fairlane (Dearborn, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    12 sites within 50 mi
  12. E-Mindfulness Approaches for Living After Breast Cancer

    NCT06748222

    • Phase 3
    • Ages 18 to 50 years
    • Sex: All

    Nearest sites: Henry Ford Hospital (Detroit, MI); Henry Ford Medical Center-Fairlane (Dearborn, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 50 mi
  13. A Study of the TheraBionic P1 Device in Breast Cancer

    NCT07218432

    • Interventional
    • Ages 22 years and older
    • Sex: Female

    Nearest sites: Karmanos Cancer Institute (Detroit, MI); Karmanos Cancer Institute Weisberg Cancer Treatment Center (Farmington Hills, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  14. A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

    NCT07227831

    • Interventional
    • Ages 22 years and older
    • Sex: All

    Nearest sites: Karmanos Cancer Institute (Detroit, MI); Karmanos Cancer Institute at McLaren Macomb (Mount Clemens, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  15. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

    NCT05208762

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Karmanos Cancer Institute (Detroit, MI); Karmanos Cancer Institute (Farmington Hills, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  16. A Phase 1/1b Study of IAM1363 in HER2 Cancers

    NCT06253871

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Henry Ford Cancer Institute (Detroit, MI); University of Michigan (Ann Arbor, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  17. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    NCT06393374

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Henry Ford Health ( Site 0010) (Detroit, MI); University of Michigan ( Site 0103) (Ann Arbor, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  18. Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

    NCT06500481

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Wayne State University/Karmanos Cancer Institute (Detroit, MI); Weisberg Cancer Treatment Center (Farmington Hills, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  19. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    NCT06827236

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Brigitte Harris Cancer Pavilion BHCP (Detroit, MI); Karmanos Cancer Institute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  20. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

    NCT07173751

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Karmanos Cancer Center (Detroit, MI); Profound Research LLC at Michigan Hematology and Oncology Consultants (Royal Oak, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  21. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    NCT05377996

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Henry Ford Health Hospital (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  22. Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

    NCT05386108

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Henry Ford Hospital (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  23. JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

    NCT05490472

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Henry Ford Health System (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  24. Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

    NCT05573126

    • Phase 1/2
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Henry Ford Hospital (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  25. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    NCT05579366

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Karmanos Cancer Institute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  26. Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

    NCT05625659

    • Interventional
    • Ages 45 to 74 years
    • Sex: Female
    • Accepts healthy volunteers

    Nearest site: Henry Ford Health (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  27. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    NCT05735080

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Karmanos Cancer Institute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  28. A Study of DB-1310 in Advanced/Metastatic Solid Tumors

    NCT05785741

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Henry Ford Health System (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  29. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    NCT05894239

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Henry Ford Hospital (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  30. A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

    NCT06103864

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Research Site (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  31. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    NCT06293898

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Karmanos Cancer Institiute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  32. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    NCT06312176

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Henry Ford Health ( Site 0002) (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  33. Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    NCT06757634

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Henry Ford Health System (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  34. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    NCT06790693

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Henry Ford Health System (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  35. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

    NCT06799065

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Karmanos Cancer Institute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  36. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

    NCT06926868

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion) (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  37. A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

    NCT07095114

    • Interventional
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Karmanos Cancer Institute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  38. A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

    NCT07102381

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Henry Ford Hospital (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  39. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    NCT07114601

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Barbara Ann Karmanos Cancer Institute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  40. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    NCT07213791

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Barbara Ann Karmanos Cancer Institute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  41. Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

    NCT07287917

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Wayne State University - Barbara Ann Karmanos Cancer Institute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  42. Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

    NCT07436078

    • Interventional
    • Ages 20 to 79 years
    • Sex: All

    Nearest site: Karmanos Cancer Institute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  43. BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

    NCT07492641

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Karmanos Cancer Institute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  44. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    NCT07503808

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Karmanos Cancer Institute (Detroit, MI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  45. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377

    • Phase 2
    • Ages Any age
    • Sex: All

    Nearest sites: Corewell Health Dearborn Hospital (Dearborn, MI); Corewell Health Children's (Royal Oak, MI)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    19 sites within 50 mi
  46. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    NCT03053193

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: St. John Hospital (Grosse Pointe Woods, MI); Beaumont Breast Care Center (Royal Oak, MI)

    Distance to nearest recruiting site
    ~11 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  47. The PREDICT Registry:

    NCT03448926

    • Observational
    • Ages 30 to 85 years
    • Sex: Female

    Nearest sites: Corewell Health William Beaumont University Center (Royal Oak, MI); Comprehensive Breast Care (Troy, MI)

    Distance to nearest recruiting site
    ~12 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  48. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    NCT06982521

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Profound Research LLC (Royal Oak, MI); University of Michigan (Ann Arbor, MI)

    Distance to nearest recruiting site
    ~12 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  49. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    NCT05633654

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: William Beaumont Hospital (Royal Oak, MI)

    Distance to nearest recruiting site
    ~12 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. Quantitative MRI Assessment of Breast Cancer Therapy Response

    NCT05704062

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: Corewell Health William Beaumont University Hospital (Royal Oak, MI)

    Distance to nearest recruiting site
    ~12 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.